CoChat

The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part I

Litvan, Irene, Halliday, Glenda, Hallett, Mark, Goetz, Christopher G., Rocca, Walter, Duyckaerts, Charles, Ben-Shlomo, Yoav, Dickson, Dennis W., Lang, Anthony E., Chesselet, Marie-Francoise, Langston, William J., Di Monte, Donato A., Gasser, Thomas, Hagg, Theo, Hardy, John, Jenner, Peter, Melamed, Eldad, Myers, Richard H., Parker, Davis, Price, Donald L. · 2007 · Journal of Neuropathology & Experimental Neurology
Cited by 125

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Abstract

We are at a critical juncture in our knowledge of the etiology and pathogenesis of Parkinson disease (PD). It is clear that PD is not a single entity simply resulting from a dopaminergic deficit; rather it is most likely caused by a combination of genetic and environmental factors and, although there is extensive new information on the etiology and pathogenesis of PD that may advance its treatment, new syntheses of this information are needed. The first part of this two-part, state-of-the-art review by leaders in Parkinson research critically examines the field to identify where new knowledge and ideas might be helpful for treatment purposes. Topics reviewed in Part I include the definition of the disease, neuropathologic contributions, and epidemiologic, environmental, and demographic issues. The definition of idiopathic Parkinson disease (PD) remains controversial. Classically, it includes a characteristic motor phenotype (1) and a distinctive neuropathology and substantial loss of dopaminergic neurons from the substantia nigra associated with the presence of α-synuclein-positive inclusions in the cell body (Lewy bodies) and processes (Lewy neurites) of specific neurons of the brainstem. Some genetically determined Parkinson syndromes resemble, sometimes closely, idiopathic PD, but differ from it neuropathologically, sometimes substantially. In particular, a number of juvenile-onset autosomal recessive cases of familial Parkinson syndrome do not have α-synuclein lesions (2), contrasting with the autosomal dominant forms of the disease which often have unusual types of lesions (3-5). The recently identified leucine-rich repeat kinase 2 (LRRK2, Park-8) mutations produce variable pathologic phenotypes. Although the most common is Lewy body disease, nigral degeneration with ubiquitin inclusions or, in a few cases, even pathologic changes more typical of frontotemporal lobar degeneration or progressive supranuclear palsy have been described in patients with LRRK2 mutations (6). Two recent reports insist on the high prevalence of Lewy bodies in the LRRK2 mutations (7) but also describe a family with tau pathology (8). Neuropathology has revealed the considerable frequency with which idiopathic PD is associated with other degenerative conditions, notably Alzheimer disease, particularly in advanced age, even though the clinical consequences of multiple pathologies remain poorly defined. Moreover, an association with genetic variants that increase tau transcription occurs in all forms of Lewy body diseases (sporadic and familial), providing additional support for the involvement of tau in the pathogenic process (9, 10). Unfortunately, the cellular mechanisms by which this or other potential detrimental processes interact to produce the features of any form of PD remain purely speculative. Other synucleinopathies (disorders with α-synuclein aggregates) include dementia with Lewy bodies (DLB), multiple system atrophy in which α-synuclein constitutes characteristic inclusions, predominantly in oligodendrocyte cell bodies (11), and neurodegeneration with brain iron accumulation in which α-synuclein accumulates in axonal spheroids (12). The recognition of such varied disorders associated with abnormal α-synuclein aggregation in multiple cell types and cell compartments has broad implications for the etiopathogenesis of this group of disorders, suggesting that the selective disruption of diverse intracellular events utilizing α-synuclein leads to distinctive anatomical and cellular patterns of pathology. In particular, some patients with DLB have patterns of α-synuclein deposition identical to those seen in idiopathic PD but have no parkinsonism (13, 14). Moreover, as olfactory dysfunction, constipation, rapid eye movement sleep behavior disorder, and depression may precede or present commonly in early PD, they are proposed to be prodromic signs of PD (15). These symptoms correlate well with the deposition of α-synuclein in Braak stages 1 (olfactory bulb and peripheral and central medullary autonomic neurons) and 2 (locus ceruleus and pontine tegmentum), which are proposed to precede the clinical symptoms of PD (stage 3 with α-synuclein deposition in the substantia nigra) (16). Should the definition of PD rely on clinical (the extrapyramidal syndrome), pathologic (the α-synuclein deposition), or genetic data? When the full spectrum of clinical PD is present, there is a high probability of finding a devastating loss of dopamine neurons (17) with α-synuclein accumulation. Moreover, the loss of nigral neurons is correlated with the severity of akinesia and rigidity (18). However, the accumulation of α-synuclein may be absent in patients with genetically determined clinical PD. Mild parkinsonian symptoms in the elderly may also relate to the loss of dopamine neurons in the absence of α-synuclein deposition (19). In most if not all of these α-synuclein-negative cases, clinical PD is determined by lesions of the nigrostriatal

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/nen.0b013e3180415e42

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 125

Metadata

Authors
Litvan, I., Halliday, G., Hallett, M., Goetz, C. G., Rocca, W., Duyckaerts, C., Ben-Shlomo, Y., Dickson, D. W., Lang, A. E., Chesselet, M.-F., Langston, W. J., Di Monte, D. A., Gasser, T., Hagg, T., Hardy, J., Jenner, P., Melamed, E., Myers, R. H., Parker, D., & Price, D. L.
Venue
Journal of Neuropathology & Experimental Neurology
Published
2007-04
Volume
66
Issue
4
Pages
251-257
ISSN
  • 0022-3069 (ISSN-L)
  • 1554-6578
OpenAlex
W1986977913
Cited by
125
References
20
FWCI
12.08
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part I. https://app.cochat.ai/papers/10.1097/nen.0b013e3180415e42
The paper
Litvan, I., Halliday, G., Hallett, M., Goetz, C. G., Rocca, W., Duyckaerts, C., Ben-Shlomo, Y., Dickson, D. W., Lang, A. E., Chesselet, M.-F., Langston, W. J., Di Monte, D. A., Gasser, T., Hagg, T., Hardy, J., Jenner, P., Melamed, E., Myers, R. H., Parker, D., & Price, D. L. (2007). The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part I. Journal of Neuropathology & Experimental Neurology. https://doi.org/10.1097/nen.0b013e3180415e42

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.